Akeso, Inc. Enjoys Bright Prospects as Favored by the Capital Market
- 2020年04月24日 19:37:00
- テクノロジー
- JCN Newswire
- コメント
Efficient R&D Platform and Strong R&D Strength
The Company is dedicated to finding solutions to treat tumors and immunological diseases. It is generally known that it takes years to develop a new drug. However, the Company has over 20 drug development programs developed in-house though it has been established for only eight years. These programs include 12 antibodies in clinical-stage development, six bi-specific antibodies (two of which are at the clinical stage), and four antibodies with IND approvals from the Food and Drug Administration (FDA). Its product pipelines cover several major diseases, such as tumors, immunological diseases, and cardiovascular diseases. It is worth mentioning that the Company has developed all its programs in-house. In November 2015, the Company became the first China-based biotech company to out-license a fully internally discovered monoclonal antibody to a world-leading pharmaceutical company as it out-licensed its CTLA-4 monoclonal antibody drug candidate (AK107) to Merck for a total consideration of up to USD200 million.
The Company's strong R&D capability is indispensable from its end-to-end ACE Platform that possesses comprehensive, the most cutting-edge functionalities in developing therapeutic antibodies. The ACE Platform encompasses drug development and manufacturing and enables seamless technology transfer from drug discovery and CMC to manufacturing. Moreover, it holds strong internal manufacturing capacity that is compliant with GMP standards regulated by the NMPA, FDA and EMA. All drugs in the clinical stage are produced in the Company's proprietary facilities in line with GMP standards.
Prominent Advantages of Core Products, Favored by the Capital Market
The key to biopharmaceutical success lies in R&D strength and efficiency. The player who takes the lead to develop a drug and obtain approval for launch, and who can prove commercialization capabilities will gain competitive edges.
The Company has developed industry-leading drugs with the ACE Platform including its core products: PD-1/CTLA-4 bi-specific antibody (AK104) and PD-1 monoclonal antibody drug, Penpulimab (AK105). Its products also encompass AK101, a promising monoclonal antibody against autoimmune diseases, and AK102 that has high potential to become the first cardiovascular drug candidate against PCSK9 developed in China.
The Company has led the world in terms of the R&D of bi-specific antibodies. Bi-specific antibodies are deemed as a second-generation antibody therapy against tumors. With respect to the research on bi-specific antibodies, the Company possesses the unique bifunctional antibody technology, Tetrabody, making it one of the few bi-specific antibody platforms verified in both manufacturing and clinical stage. According to clinical observation, compared with the combined therapy of Nivolumab and Ipilimumab, AK104 has demonstrated better safety and efficacy. As of September 30, 2019, over 90 bi-specific antibodies were undergoing clinic trial. Nevertheless, no PD-(L)-based bi-specific antibodies had been approved for market launch. AK104 is the world's first bi-specific antibody drug that is in the clinical trial stage. It is expected that the first new drug application (NDA) of AK104 of the Company for treating cervical cancer will result in first-mover advantage.
AK105 of the Company is a monoclonal antibody currently in late-stage clinical development. PD-1 monoclonal antibody drugs are experiencing fierce competition, as six PD-1 drugs have been launched in China. Despite the extensively competitive market, AK105 is still favored for its strong efficacy and high safety. Therefore, Sino Biopharmaceutical Limited, a HK-listed pharmaceutical leader, has cooperated with the Company to jointly develop and commercialize AK105. AK105 of the Company is the only PD-1 antibody that Sino Biopharm can use to develop PD-1-based monotherapy or combination therapy, which evidences the great commercial potential of AK105. After the new drug is launched, the wide online sale channels and immense commercial capability of Sino Biopharmaceutical Limited will be utilized by the Company to maximize the commercial value of AK105.
Thanks to its strong R&D strength and commercialization capabilities, the Company has been favored by the capital market. Through Series D financing in November last year, the Company raised USD126 million in total, with the leading investor being Sino Biopharmaceutical Limited. Medical funds like Lake Bleu Capital, OrbiMed, and AIHC Capital participated in the financing. The Company's valuation reached USD836 million after Series D financing and became nearly 18 times as high as that after Series A financing of RMB330 million in just four years. Especially, Shenzhen Capital Group Co., Ltd. (SCGC), a leading venture capital firm in China that was co-founded by the Shenzhen Municipal Government and a group of private partners, participated in every series of financing. Relevant funds under K. Wah Group became a shareholder of Akeso in the series of financing before the IPO. This also means that K. Wah Group has set foot in the healthcare sector. Investment from famous capital holders reflect Akeso's bright future.
Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com
前田日明氏“大物横綱襲撃計画”を実名告白「後ろからそっと行ってこうやった瞬間…」
36歳金髪女性タレント「散々おもちゃに…」大物コンビにイジり倒され、ブチ切れ&爆笑「最高」
サンド伊達みきお、会社員時代「有給休暇の提出なんか…」平日4日休んでGW11連休に複雑な思い
「たまんなく可愛い」本田翼が絶対領域ミニワンピ&ニーハイ姿でダンス「透明感」肌ケア動画も
松平健、遊園地で初の「マツケンサンバⅡ」に「自分でも感動」 万博でのパフォーマンスにも意欲
【日本ハム】清宮幸太郎が今季初の「1番三塁」…ロッテ小島には昨季打率4割/スタメン一覧
【巨人】今季の対阪神戦連敗ストップへ、門脇誠が「8番三塁」でスタメン復帰 先発は石川達也
【ソフトバンク】開幕19試合連続安打中の周東佑京、2戦連続でベンチスタート
大谷翔平は4打数無安打…4打席目はスライダー打ち上げ中飛 登場曲は真美子夫人チョイス
ドジャース、ドラフト全米2位29歳センゼルとマイナー契約 今季メキシカンリーグで驚異的成績
多部未華子(30)結婚の裏事情あまりにも恐ろしすぎると話題に!
77歳「ウルトラセブンのアンヌ隊員」76歳「仮面ライダーアマゾン」と結婚へ「地球も平和だ」
ギャル曽根、不倫されても「離婚は絶対しない」驚きの理由「考えてもみなかった方法」と夫
二階堂ふみが結婚!?お相手が衝撃的過ぎてネット民「マジか・・・」
永野芽郁と田中圭の所属事務所が不倫報道を否定「友人関係です」
松山千春、石橋貴明めぐる騒動に言及「業界の仲間でも何人かいるな。脱ぐのはいいんだけど…」
永野芽郁に「二股不倫」報道 TBSドラマ「キャスター」出演は「変更ありません」回答
武田鉄矢「金八先生」シリーズ1位の“天才生徒”を実名発表「もう群を抜いていて…」
“役満ボディー”岡田紗佳、大胆な下着ショットを公開に「セクシー」「わがままボディー」反響
62歳ボディメークトレーナー、露出度高めの写真に反響「60代だなんてホント信じられない!」
多部未華子(30)結婚の裏事情あまりにも恐ろしすぎると話題に!
二階堂ふみが結婚!?お相手が衝撃的過ぎてネット民「マジか・・・」
小澤征悦と再婚した桑子真帆アナ(34)黒い過去が流出、衝撃の過去にネット騒然
俳優の板垣瑞生さん、不慮の事故により逝去 家族がインスタで発表 今年1月末から行方不明に
孤独のグルメで旨そうだった「トマトの酢漬け」のおいしい作り方! フレッシュな旨味がキューッとくるっ
昨年引退した元AV男優しみけん「やめてよかったですか?」問いに即答「うん」その理由とは?
【おすすめアニメ50選】完結済み!定番から最新作まで!
「名探偵コナン」最大の謎、蘭姉ちゃんのあの角の正体がついに判明
42歳ブレイキングダウン選手、東京駅でケンカ売られ取った行動に「尊敬する」「真似しよ」X拍手
八代亜紀さんのヌード写真封入アルバム発売、所属事務所が「警察にも相談中」公式コメントを発表

前田日明氏“大物横綱襲撃計画”を実名告白「後ろからそっと行ってこうやった瞬間…」
36歳金髪女性タレント「散々おもちゃに…」大物コンビにイジり倒され、ブチ切れ&爆笑「最高」
サンド伊達みきお、会社員時代「有給休暇の提出なんか…」平日4日休んでGW11連休に複雑な思い
「たまんなく可愛い」本田翼が絶対領域ミニワンピ&ニーハイ姿でダンス「透明感」肌ケア動画も
松平健、遊園地で初の「マツケンサンバⅡ」に「自分でも感動」 万博でのパフォーマンスにも意欲
【日本ハム】清宮幸太郎が今季初の「1番三塁」…ロッテ小島には昨季打率4割/スタメン一覧
【巨人】今季の対阪神戦連敗ストップへ、門脇誠が「8番三塁」でスタメン復帰 先発は石川達也
【ソフトバンク】開幕19試合連続安打中の周東佑京、2戦連続でベンチスタート
大谷翔平は4打数無安打…4打席目はスライダー打ち上げ中飛 登場曲は真美子夫人チョイス
多部未華子(30)結婚の裏事情あまりにも恐ろしすぎると話題に!